瑞科生物
RECBIO

Jiangsu Recbio Technology Co., Ltd.
江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02179)

ANNOUNCEMENT ON THE ESTIMATED RESULTS FOR THE FIRST HALF OF 2026

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the "**Company**", together with its subsidiaries, collectively referred to as the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the provisions relating to inside information (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Set out below is the estimated results of the Group for the six months ended June 30, 2026 (the "**Reporting Period**").

I. ESTIMATED RESULTS FOR THE FIRST HALF OF 2026

(1) The period for the estimated results

January 1, 2026 to June 30, 2026

(2) Estimated results: loss is expected to be recorded, but is narrowed compared with the same period of last year

Item	**Reporting Period** *(RMB'000)*	**Same Period Last Year** *(RMB'000)*	**Range of Change**
Revenue	40-54	10,899	Reduced by approximately 99.50% to 99.63%
Other income and gains	9,542-10,546	12,102	Reduced by approximately 12.86% to 21.16%
Loss before tax	(222,183)-(201,023)	(339,573)	Narrowed by approximately 34.57% to 40.80%
Loss for the period	(222,412)-(201,230)	(340,653)	Narrowed by approximately 34.71% to 40.93%
Loss attributable to owners of the parent	(222,412)-(201,230)	(340,653)	Narrowed by approximately 34.71% to 40.93%
Loss per share – Basic and diluted (RMB)	(0.36)-(0.33)	(0.71)	Narrowed by approximately 49.14% to 53.98%

II. MAIN REASONS FOR CHANGES IN RESULTS

During the Reporting Period, the loss narrowed year-on-year, mainly because the main work and large-scale investment phase of the clinical trials for the Company's core products were completed as planned. As some projects shifted focus toward registration review and commercialization preparations, R&D investment decreased accordingly. At the same time, the revenue decreased year-on-year during the Reporting Period, due to the fact that the Company recognized a revenue from external licensing of intellectual property rights in the same period of last year, the similar licensing business was in progress but had not yet met the revenue recognition conditions during the Reporting Period. Overall, the loss has been narrowed, but further improvement is still required.

III. RISK WARNING

The financial data published in this announcement are preliminary estimation, which have not been audited by an accounting firm. For specific financial data, please refer to the 2026 interim report to be disclosed by the Company. As of the date of this announcement, the Company has not found any major uncertainties that would affect the accuracy of the estimated results.

Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Mr. XU Haoyu
Chairman

Jiangsu Province, the PRC, July 31, 2026

As at the date of this announcement, the Board comprises Mr. XU Haoyu as the chairman of the Board and a non-executive director, Dr. LIU Yong, Ms. WANG Jing and Mr. WEI Qifang as executive directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive directors.